|Bid||451.51 x 1100|
|Ask||453.40 x 2200|
|Day's Range||442.00 - 454.60|
|52 Week Range||250.21 - 532.57|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||37.18|
|Earnings Date||Jan 28, 2021 - Feb 01, 2021|
|Forward Dividend & Yield||0.88 (0.19%)|
|Ex-Dividend Date||Dec 14, 2020|
|1y Target Est||503.00|
Investors continue to be optimistic about Bio-Rad (BIO) on robust growth of the Life Science segment and a solid testing portfolio.
LabCorp's (LH) Patient Direct offering will be used here to help in bringing suitable clinical trials to eligible patients directly.
Investors continue to be positive about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.